Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626784 | 0.98 | EGFR (0.39) | KDM4EHTTSMN1; SMN2ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL7229751 | 0.90 | EGFR (0.44) | KDM4EMAPTEGFRMEN1KMT2A | |
| SCHEMBL2626789 | 0.88 | EGFR (0.46) | KDM4EMAPTEGFRMEN1KMT2A | |
| Iodide SCHEMBL30367691 | 0.86 | EGFR (0.44) | KDM4EMAPTEGFRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL40555 | 0.84 | MAPT (0.50) | KDM4EHTTSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30165715 | 0.82 | KMT2A (0.50) | KDM4EHTTSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL146313 | 0.82 | KMT2A (0.50) | KDM4EHTTSMN1; SMN2ALDH1A1TP53 | |
| Iodide SCHEMBL11279046 | 0.80 | KMT2A (0.48) | KDM4EHTTSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL13097886 | 0.80 | APAF1 (0.40) | KDM4ESMN1; SMN2ALDH1A1MAPTCASP1 | |
| Hydrochloric Acid SCHEMBL41927 | 0.78 | TERT (0.43) | EGFRMEN1KMT2APOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1758 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097043-A1 | NOVEL FORMULATIONS AND VEHICLES | WISTA LABORATORIES LTD. (SG) | 2026-04-09 | — | — | US | claimed |
| US-12569371-B2 | Sterilization of medical dressings with enhanced antimicrobial properties | HYDROFERA, LLC (US) | 2026-03-10 | — | — | US | claimed |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | WISTA LABORATORIES LTD (SG) | 2026-02-19 | — | — | US | claimed |
| EP-4165465-B1 | SYSTEMS AND METHODS FOR INDICATING THE TIME ELAPSED SINCE THE OCCURRENCE OF A TRIGGERING EVENT | JOHNSON & JOHNSON VISION CARE (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250270177-A1 | PURIFICATION METHOD FOR ELECTRON MEDIATOR | LEADWAY (HK) LIMITED (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2025-08-21 | — | — | US | claimed |
| US-12384701-B2 | Ion removal devices based on electrochemistry and photo-electrochemistry, and preparation method and application | SOUTH CHINA NORMAL UNIVERSITY (CN) | 2025-08-12 | — | — | US | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4590275-A1 | NOVEL FORMULATIONS AND VEHICLES | WisTa Laboratories Ltd. (SG) | 2025-07-30 | — | — | EP | claimed |
| US-20250222006-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | WISTA LABORATORIES LTD. (SG) | 2025-07-10 | — | — | US | claimed |
| EP-0314293-A2 | A kit and method for analyses of biological specimens | CELL ANALYSIS SYSTEMS, INC. (US) | 1989-05-03 | — | — | EP | claimed |
| US-4816244-A | Stabilized stain solutions containing aliphatic and aromatic alcohols | SIGMA CHEMICAL COMPANY (US) | 1989-03-28 | — | — | US | claimed |
| US-4741898-A | ANIONIC AND CATIONIC DYES, ALCOHOL AND LYSINE OR GLYCINE | FISHER SCIENTIFIC COMPANY (US) | 1988-05-03 | — | — | US | claimed |
| EP-0086951-B1 | STABILIZED ROMANOWSKY STAIN SOLUTION AND METHOD OF PREPARATION THEREOF | MILES LABORATORIES, INC. (US) | 1985-10-30 | — | — | EP | claimed |
| US-4548927-A | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics | EATON JOHN W (US) | 1985-10-22 | — | — | US | claimed |
| EP-0144402-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON, John W. (US) | 1985-06-19 | — | — | EP | claimed |
| WO-1984004679-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON JOHN W | 1984-12-06 | — | — | WO | claimed |
| EP-0086951-A1 | Stabilized Romanowsky stain solution and method of preparation thereof | MILES LABORATORIES, INC. (US) | 1983-08-31 | — | — | EP | claimed |
| US-4392864-A | Stabilized Romanowsky stain solution | MILES LABORATORIES, INC. (US) | 1983-07-12 | — | — | US | claimed |
| US-4003892-A | Method of separating thionine and its N-methyl derivatives from each other | SERVA-ENTWICKLUNGSLABOR V. GROTHE & CO. (DT) | 1977-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569371-B2 | Sterilization of medical dressings with enhanced antimicrobial properties | ACR, CD47, CD99 | CHRM2 1318/4885ACHE 1815/4885SLC6A2 3356/4885 |
| US-20250222006-A1 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | MB, TPMT, HBB | CHRM2 2324/4885ACHE 1987/4885SLC6A2 1063/4885 |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | MAPT, PARK7, TARDBP | CHRM2 1892/4885ACHE 25/4885SLC6A2 354/4885 |
| US-20250270177-A1 | PURIFICATION METHOD FOR ELECTRON MEDIATOR | MB, DAO, BCAT2 | CHRM2 3360/4885ACHE 2962/4885SLC6A2 2689/4885 |
| US-20260097043-A1 | NOVEL FORMULATIONS AND VEHICLES | TPMT, PARK7, HTT | CHRM2 1859/4885ACHE 249/4885SLC6A2 415/4885 |
| US-20250262219-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | CHRM2 97/4885ACHE 1/4885SLC6A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.